DGAP-Adhoc

Biotest AG: Correction of the Ad hoc announcement dated February 11th 2016: Accidentally an incorrect preliminary and unaudited EBIT for the fiscal year 2015 was published. The EBIT amounts to EUR -71.8 million and not to EUR -72.3 million. Below, the cor

Biotest AG / Key word(s): Preliminary Results

11.02.2016 15:52

Dissemination of a Ad-hoc-correction according to § 15 WpHG, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc RELEASE
Announcement according to § 15 Sec. 1 Securities Trading Act (WpHG)

Correction of the Ad hoc announcement dated February 11th 2016:
Accidentally an incorrect preliminary and unaudited EBIT for the fiscal
year 2015 was published. The EBIT amounts to EUR -71.8 million and not to
EUR -72.3 million. Below, the corrected announcement:

Biotest exceeds EBIT guidance for 4th quarter 2015

Dreieich, 11. February 2016. According to preliminary and unaudited
figures, the Biotest Group exceeds its EBIT guidance published in November
2015 in the amount of EUR 5-10 million for the fourth quarter 2015 and
reports an EBIT of EUR 10.2 million in the fourth quarter 2015. The
revenues came in at EUR 171.7 million, which is on the previous year's
level of EUR 172.1 million.

According to preliminary and unaudited figures, the Biotest Group increased
revenues in the full year 2015 to EUR 589.6 million. This represents an
increase of 1.3 % compared to the previous year (2014: EUR 582.0 million).

On account of an unscheduled write down and impairment in the third quarter
2015 in the amount of EUR 84 million and the termination of the cooperation
with AbbVie the preliminary and unaudited Group's earnings before interest
and tax (EBIT) stand at - EUR 71.8 million (2014: EUR 53.4 million).

Biotest will publish final results for the Financial Year 2015 and the
annual report on March 23rd, 2016.

Biotest Aktiengesellschaft
Board of Management

Biotest AG
Landsteinerstr. 5
D-63303 Dreieich
www.biotest.de

Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.

About Biotest
Biotest is a provider of plasma proteins and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
clinical immunology, haematology and intensive medicine. Biotest develops
and markets immunoglobulins, coagulation factors and albumins based on
human blood plasma. These are used for diseases of the immune and
haematopoietic systems. In addition Biotest develops monoclonal antibodies
in the indications of cancer of plasma cells and Systemic lupus
erythomatosus, which are produced by recombinant technologies. Biotest has
more than 2.200 employees worldwide. The preference shares of Biotest AG
are listed in the SDAX on the Frankfurt stock exchange.
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart


11.02.2016 The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------

Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: [e-mail]
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------